Founder: Curzio Rüegg
Early detection of breast cancer with a blood test
Mr Ruegg and his team have developed a blood test for breast cancer screening and early detection of relapse. This test is based on the analysis of multiple specific biomarkers derived from blood leukocytes. It can be integrated into current diagnostic procedures and will help doctors make decisions for personalized treatments.
Xemperia is a spin-off project from the University of Fribourg. Its aim is to introduce a new generation of diagnostic solutions in medicine for the benefit of patients and society. It draws on over 25 years’ experience in experimental and translational breast cancer research and biomarker discovery. The project is led by the University of Freiburg team in collaboration with clinical partners.
